Controversy about the relationship between sulfonylurea use and cardiovascular events and mortality

Among a number of classes of oral antihyperglycemic drugs, sulfonylureas (SUs) demonstrating the potential effect to reduce blood glucose level have been used in a majority of patients with type 2 diabetes for many years. The pathophysiological processes by which SUs adversely induce the risk of cardiovascular disease have not been fully clarified. We summarized about the relationship between SU use and cardiovascular events and mortality in patients with type 2 diabetes.